PTH and bortezomib suppress growth of primary human myeloma through increased bone formation in vivo.

被引：0
|
作者：
Pennisi, Angela [1 ]
Ling, Wen [1 ]
Perkins, Paul [1 ]
Saha, Rinku [1 ]
Li, Xin [1 ]
Barlogie, Bart [1 ]
Tricot, Guido [1 ]
Zangari, Maurizio [1 ]
Yaccoby, Shmuel [1 ]
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Theraphy, Little Rock, AR 72205 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
509
引用
收藏
页码：154A / 154A
页数：1
相关论文
共 50 条
  • [31] Tob-deficiency prevents ovariectomy-induced bone loss through the enhancement of osteoblastic differentiation in bone marrow stromal cells to augment bone formation (BFR/MAR) in vivo.
    Usui, M
    Yoshida, Y
    Tsuji, K
    Ishikawa, I
    Nifuji, A
    Yamamoto, T
    Noda, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S133 - S133
  • [32] BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE AS PRIMARY INDUCTION THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA SIGNIFICANTLY DECREASES BONE RESORPTION WHILE SPARING BONE FORMATION AS COMPARED TO THALIDOMIDE-DEXAMETHASONE
    Tosi, P.
    Zamagni, E.
    Tacchetti, P.
    Perrone, G.
    Ceccolini, M.
    Brioli, A.
    Pallotti, M.
    Pantani, L.
    Petrucci, A.
    Baccarani, M.
    Cavo, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 265 - 265
  • [33] Increased Expression of TAF12 in the Bone Microenvironment in Multiple Myeloma Enhances Tumor Cell Growth and Osteoclast Formation.
    Kitagawa, Yukiko
    Teramachi, Jumpei
    Windle, Jolene
    Chirgwin, John
    Roodman, G. David
    Kurihara, Noriyoshi
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S372 - S372
  • [34] Blocking the ZZ domain of sequestosome 1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo
    Teramachi, J.
    Silbermann, R.
    Yang, P.
    Zhao, W.
    Mohammad, K. S.
    Guo, J.
    Anderson, J. L.
    Zhou, D.
    Feng, R.
    Myint, K-Z
    Maertz, N.
    Beumer, J. H.
    Eisemans, J. L.
    Windle, J. J.
    Xie, X-Q
    Roodman, G. D.
    Kurihara, N.
    LEUKEMIA, 2016, 30 (02) : 390 - 398
  • [35] Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo
    J Teramachi
    R Silbermann
    P Yang
    W Zhao
    K S Mohammad
    J Guo
    J L Anderson
    D Zhou
    R Feng
    K-Z Myint
    N Maertz
    J H Beumer
    J L Eiseman
    J J Windle
    X-Q Xie
    G D Roodman
    N Kurihara
    Leukemia, 2016, 30 : 390 - 398
  • [36] Blocking DKK1 activity in primary myeloma-bearing SCID-rab mice is associated with increased osteoblast activity and bone formation, and inhibition of tumor growth.
    Yaccoby, S
    Zhan, F
    Barlogie, B
    Shaughnessy, JD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S33 - S33
  • [37] Inhibition of DKK1 activity is associated with increased osteoblast numbers and bone formation, reduced osteoclast activity and inhibition of tumor growth in the SCID-rab model for primary myeloma.
    Yaccoby, S
    Ling, W
    Saha, R
    Zhan, FH
    Walker, R
    Tricot, G
    Barlogie, B
    Shaughnessy, JD
    BLOOD, 2005, 106 (11) : 189A - 189A
  • [38] Ex Vivo Evaluation of VLA-4 Expression in Primary Human Multiple Myeloma Bone Marrow Samples and In Vivo Mobilization of Murine Multiple Myeloma Cells with Small Molecule VLA-4 Inhibitors
    Chanswangphuwana, Chantiya
    Rettig, Michael P.
    Akers, Walter
    Hathi, Deep
    Holt, Matthew
    O'Neal, Julie
    Ritchey, Julie
    Kohnen, Danny
    King, Justin A.
    Tomasson, Michael H.
    Vij, Ravi
    Shokeen, Monica
    DiPersio, John F.
    BLOOD, 2016, 128 (22)
  • [39] Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation
    Ma, YFL
    Cain, RL
    Halladay, DL
    Yang, XH
    Zeng, QQ
    Miles, RR
    Chandrasekhar, S
    Martin, TJ
    Onyia, JE
    ENDOCRINOLOGY, 2001, 142 (09) : 4047 - 4054
  • [40] Combination therapy with an antibody specific for transferrin receptor 1 (ch128.1/IgG1) and bortezomib or lenalidomide results in increased survival in an in vivo model of human multiple myeloma
    Candelaria, Pierre, V
    Nava, Miguel
    Martinez-Maza, Otoniel
    Daniels-Wells, Tracy R.
    Penichet, Manuel L.
    CANCER RESEARCH, 2020, 80 (16)
12345